Opinion: STAT+: The future of pharma and health care will come in small (molecule) packages

Hybrid therapies — small molecule medicines supplemented by complex biologics — could enable new combinatorial approaches to cancer, neurodegeneration, and even aging.

Rightful accolades to Moderna and Pfizer/BioNTech for the Covid-19 vaccines they created and developed in less than a year, along with plans to use their technologies to fight other infectious diseases, such as AIDS, and even to treat cancer, have renewed enthusiasm for complex therapies. But I believe that complex therapies, for all their wonders, represent only part of the future of medicine.

Modern medicines are split into two big families: biologics and small-molecule drugs.

Continue to STAT+ to read the full story…